High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Statins reduce the incidence of strokes among patients at increased risk for cardiovascular disease; whether they reduce the risk of stroke after a recent stroke or transient ischemic attack (TIA) remains to be established. METHODS: We randomly assigned 4731 patients who had had a stroke or TIA within one to six months before study entry, had low-density lipoprotein (LDL) cholesterol levels of 100 to 190 mg per deciliter (2.6 to 4.9 mmol per liter), and had no known coronary heart disease to double-blind treatment with 80 mg of atorvastatin per day or placebo. The primary end point was a first nonfatal or fatal stroke. RESULTS: The mean LDL cholesterol level during the trial was 73 mg per deciliter (1.9 mmol per liter) among patients receiving atorvastatin and 129 mg per deciliter (3.3 mmol per liter) among patients receiving placebo. During a median follow-up of 4.9 years, 265 patients (11.2 percent) receiving atorvastatin and 311 patients (13.1 percent) receiving placebo had a fatal or nonfatal stroke (5-year absolute reduction in risk, 2.2 percent; adjusted hazard ratio, 0.84; 95 percent confidence interval, 0.71 to 0.99; P=0.03; unadjusted P=0.05). The atorvastatin group had 218 ischemic strokes and 55 hemorrhagic strokes, whereas the placebo group had 274 ischemic strokes and 33 hemorrhagic strokes. The five-year absolute reduction in the risk of major cardiovascular events was 3.5 percent (hazard ratio, 0.80; 95 percent confidence interval, 0.69 to 0.92; P=0.002). The overall mortality rate was similar, with 216 deaths in the atorvastatin group and 211 deaths in the placebo group (P=0.98), as were the rates of serious adverse events. Elevated liver enzyme values were more common in patients taking atorvastatin. CONCLUSIONS: In patients with recent stroke or TIA and without known coronary heart disease, 80 mg of atorvastatin per day reduced the overall incidence of strokes and of cardiovascular events, despite a small increase in the incidence of hemorrhagic stroke. (ClinicalTrials.gov number, NCT00147602 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the recently published Lipitor's Effect in Alzheimer's Dementia (LEADe) trial, which included 640 randomized patients with mild Alzheimer disease, intensive lipid lowering by the addition of atorvastatin (80 mg) to donepezil did not improve cognitive function over a 72-week period.464”
In the citing paper
“Data from RCTs and meta-analyses indicate that routine early use of high-intensity statin therapy is associated with rapid and sustained clinical benefits [438-442].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [438]
In the citing paper
“Following stroke or TIA, 34 patients are at risk not only of recurrent cerebrovascular events but also of other major CV events including MI.”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [34]
In the citing paper
“Secondary prevention therapy with statins reduces the risk of recurrent stroke (by 12%), MI and vascular death.422,428”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [428]
In the citing paper
“Many reports have also indicated that there is no clear relationship between the TG level and cerebrovascular disease856, 862, 863).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [862]
Citations
Cites
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Cerebral Vascular Accidents in Patients over the Age of 60: II. Prognosis
Rankin, J. (1957) · Scottish Medical Journal · doi:10.1177/003693305700200504 · Cited by 2,506
Sacco, R. L., Adams, R., Albers, G., Alberts, M. J., Benavente, O., Furie, K., Goldstein, L. B., Gorelick, P., Halperin, J., Harbaugh, R., et al. (2006) · Stroke · doi:10.1161/01.str.0000199147.30016.74 · Cited by 1,873
Iso, H., Jacobs, D. R., Wentworth, D., Neaton, J. D., Cohen, J. D., & for the MRFIT Research Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198904063201405 · Cited by 1,133
Amarenco, P., Labreuche, J., Lavallée, P., & Touboul, P.-J. (2004) · Stroke · doi:10.1161/01.str.0000147965.52712.fa · Cited by 746
Research works printed but not linked: 1
- Waters DD, 2005, Circulation, 112, 2020
Cited by
Items 501–600 of 1,005
Aspirin in Alzheimer’s Disease: Increased Risk of Intracerebral Hemorrhage: Cause for Concern?
Thoonsen, H., Richard, E., Bentham, P., Gray, R. G., van Geloven, N., de Haan, R. J., van Gool, W. A., & Nederkoorn, P. J. (2010) · Stroke · doi:10.1161/strokeaha.109.576975 · Cited by 62
Statin Treatment, New-Onset Diabetes, and Other Adverse Effects: A Systematic Review
Bang, C. N., & Okin, P. M. (2014) · Current Cardiology Reports · doi:10.1007/s11886-013-0461-4 · Cited by 61
van Boven, J. F. M., Stuurman-Bieze, A. G. G., Hiddink, E., Postma, M. J., & Vegter, S. (2014) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2014.20.8.786 · Cited by 57
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
Provencio, J. J. (2007) · Yearbook of Critical Care Medicine · doi:10.1016/s0734-3299(08)70393-9 · Cited by 57
Chang, J. J., Katsanos, A. H., Khorchid, Y. M., Dillard, K., Kerro, A., Burgess, L. G., Goyal, N., Alexandrov, A. W., Alexandrov, A. V., & Tsivgoulis, G. K. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.12.008 · Cited by 56
Flint, A. C., Conell, C., Ren, X., Kamel, H., Chan, S. L., Rao, V. A., & Johnston, S. C. (2017) · Stroke · doi:10.1161/strokeaha.117.017343 · Cited by 56
Lipids, Apolipoproteins, Statins, and Intracerebral Hemorrhage: A Mendelian Randomization Study
Zhou, Y., Zhang, L., Zhang, G., Xia, K., Yang, Q., Huang, T., & Fan, D. (2022) · Annals of Neurology · doi:10.1002/ana.26426 · Cited by 56
Overcoming Challenges With Statin Therapy
Spence, J. D., & Dresser, G. K. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002497 · Cited by 61
Is it Time for a Cardiovascular Primary Prevention Trial in the Elderly?
Robinson, J. G., Bakris, G. L., Torner, J., Stone, N. J., & Wallace, R. B. (2006) · Stroke · doi:10.1161/01.str.0000254602.58896.d2 · Cited by 59
Kim, H. W., Regenhardt, R. W., D’Amato, S. A., Nahhas, M. I., Dmytriw, A. A., Hirsch, J. A., Silverman, S. B., & Martínez-Gutiérrez, J. C. (2022) · Journal of NeuroInterventional Surgery · doi:10.1136/jnis-2022-018732 · Cited by 54
Pharmacologic treatment of hyperlipidemia.
Last, A. R., Ference, J. D., & Falleroni, J. (2011) · PubMed · Cited by 69
Outcomes After Stroke: Risk of Recurrent Ischemic Stroke and Other Events
Elkind, M. S. V. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.02.005 · Cited by 59
Lo, S., Chu, S.-W., Muo, C., Meng, N., Chou, L., Huang, W.-C., Huang, C., & Sung, F. (2013) · Rheumatology International · doi:10.1007/s00296-013-2847-4 · Cited by 55
Clinical trials for preventing post stroke cognitive impairment
Ankolekar, S., Geeganage, C. M., Anderton, P., Hogg, C., & Bath, P. M. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2010.08.052 · Cited by 62
Raine, R., Wong, W., Ambler, G., Hardoon, S. L., Petersen, I., Morris, R. W., Bartley, M., & Blane, D. (2009) · BMJ · doi:10.1136/bmj.b1279 · Cited by 57
Recommendations and treatment strategies for the management of acute ischemic stroke
Segura, T., Calleja, S., & Jordán, J. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.7.1071 · Cited by 62
Asymptomatic Carotid Stenosis: Intervention or Best Medical Therapy?
Gaba, K., Ringleb, P. A., & Halliday, A. W. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0888-5 · Cited by 61
Statin therapy: does sex matter?
Faubion, S. S., Kapoor, E., Moyer, A. M., Hodis, H. N., & Miller, V. M. (2019) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001412 · Cited by 61
“On the contrary, statins may increase the risk for hemorrhagic stroke.(41,42)”
BackgroundSatoh, M., Ohkubo, T., Asayama, K., Murakami, Y., Sakurai, M., Nakagawa, H., Iso, H., Okayama, A., Miura, K., Imai, Y., et al. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.04639 · Cited by 54
Cheng, S. F., van Velzen, T. J., Gregson, J., Richards, T., Jäger, H. R., Simister, R. J., Kooi, M. E., de Borst, G. J., Pizzini, F. B., Nederkoorn, P. J., et al. (2022) · Trials · doi:10.1186/s13063-022-06429-z · Cited by 54
Clinical considerations in early-onset cerebral amyloid angiopathy
Banerjee, G., Collinge, J., Fox, N. C., Lashley, T., Mead, S., Schott, J. M., Werring, D. J., & Ryan, N. S. (2023) · Brain · doi:10.1093/brain/awad193 · Cited by 61
Martínez‐Ramírez, S., Delgado‐Mederos, R., Marín, R., Suárez‐Calvet, M., Sáinz, M. P., Alejaldre, A., Vidal‐Jordana, Á., Jl, M.-V., & Martí‐Fábregas, J. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6137-3 · Cited by 56
“Statins are mainly effective in long-term primary and secondary prevention of ischemic stroke [5, 6], but their pleiotropic effects could attenuate the ischemic damage in the acute phase of stroke [7] and promote brain tissue repair [8].”
BackgroundCommunity-Dwelling Stroke Survivors: Function Is Not the Whole Story With Quality of Life
White, J. H., Alston, M. K., Marquez, J. L., Sweetapple, A. L., Pollack, M. R. P., Attia, J., Levi, C. R., Sturm, J. W., & Whyte, S. (2007) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2007.06.003 · Cited by 58
Turan, T. N., Lynn, M., Nizam, A., Lane, B. F., Egan, B. M., Le, N., Lopes-Virella, M. F., Hermayer, K. L., Benavente, O., White, C. L., et al. (2012) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.966911 · Cited by 54
Amarenco, P., Goldstein, L. B., Sillesen, H. H., Benavente, O., Zweifler, R. M., Callahan, A., Hennerici, M. G., Zivin, J. A., & Welch, K. M. A. (2010) · Stroke · doi:10.1161/strokeaha.109.564781 · Cited by 58
Lipid-Lowering Drugs in Ischemic Stroke Prevention and Their Influence on Acute Stroke Outcome
Fuentes, B., Martínez‐Sánchez, P., & Díez‐Tejedor, E. (2009) · Cerebrovascular Diseases · doi:10.1159/000200450 · Cited by 56
Miura, T., Soga, Y., Doijiri, T., Aihara, H., Yokoi, H., Iwabuchi, M., & Nobuyoshi, M. (2012) · Circulation Journal · doi:10.1253/circj.cj-12-0535 · Cited by 60
Contemporary Results of Carotid Endarterectomy for Asymptomatic Carotid Stenosis
Woo, K., Garg, J., Hye, R. J., & Dilley, R. B. (2010) · Stroke · doi:10.1161/strokeaha.110.578856 · Cited by 54
Alpérovitch, A., Kurth, T., Bertrand, M., Ancelin, M., Helmer, C., Debette, S., & Tzourio, C. (2015) · BMJ · doi:10.1136/bmj.h2335 · Cited by 60
Neuroprotective and neurotrophic curcuminoids to treat stroke: a translational perspective
Lapchak, P. A. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.542410 · Cited by 58
The Success Story of LDL Cholesterol Lowering
Pedersen, T. R. (2016) · Circulation Research · doi:10.1161/circresaha.115.306297 · Cited by 56
Byun, Y. S., Yang, X., Bao, W., DeMicco, D. A., Laskey, R. E., Witztum, J. L., & Tsimikas, S. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.057 · Cited by 59
Milionis, H. J., Ntaios, G., Korompoki, E., Vemmos, K. N., & Michel, P. (2019) · International Journal of Stroke · doi:10.1177/1747493019873594 · Cited by 61
Sharrief, A. Z., & Grotta, J. C. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804766-8.00021-2 · Cited by 70
Seo, W., Yong, H. S., Koh, S., Suh, S., Kim, J. H., Yu, S.-W., & Lee, J. (2008) · European Neurology · doi:10.1159/000121418 · Cited by 54
Marais, A. D., Kim, J. B., Wasserman, S. M., & Lambert, G. C. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.004 · Cited by 57
Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond
Safarova, M. S., Bimal, T., Soffer, D. E., Hirsh, B. J., Shapiro, M. D., Mintz, G. L., Cha, A., & Gianos, E. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100701 · Cited by 54
“Moreover, it can modestly reduce hs-CRP levels when used in combination with statins [89,90].”
BackgroundPROactive: time for a critical appraisal
Betteridge, D. J., DeFronzo, R. A., & CHILTON, R. J. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn114 · Cited by 57
Optimal Treatment of Carotid Artery Disease
Levy, E. I., Mocco, J., Samuelson, R. M., Ecker, R. D., Jahromi, B. S., & Hopkins, L. N. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.10.052 · Cited by 57
Cai, R., Yuan, Y., Zhou, Y., Xia, W., Wang, P., Sun, H., Yang, Y., Huang, R., & Wang, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104922 · Cited by 57
O'Brien, E. C., Greiner, M. A., Xian, Y., Fonarow, G. C., Olson, D. M., Schwamm, L. H., Bhatt, D. L., Smith, E. E., Maisch, L., Hannah, D., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.016183 · Cited by 53
“The results from our analyses of any statin therapy are consistent with previous work that has demonstrated the clinical benefit of statin use after ischemic stroke, including a retrospective analysis from the Heart Protection Study that reported a 20% lower risk of major vascular events in patients receiving simvasta…”
ResultAdherence to antihypertensive agents after ischemic stroke and risk of cardiovascular outcomes
Perreault, S., Yu, A., Côté, R., Dragomir, A., White‐Guay, B., & Dumas, S. (2012) · Neurology · doi:10.1212/wnl.0b013e3182749e56 · Cited by 56
Statins Promote the Growth of Experimentally Induced Cerebral Aneurysms in Estrogen-Deficient Rats
Tada, Y., Kitazato, K. T., Yagi, K., Shimada, K., Matsushita, N., Kinouchi, T., Kanematsu, Y., Satomi, J., Kageji, T., & Nagahiro, S. (2011) · Stroke · doi:10.1161/strokeaha.110.608034 · Cited by 53
Zhao, W., An, Z., Hong, Y., Zhou, G., Guo, J., Zhang, Y., Yang, Y., Ning, X., & Wang, J. (2016) · BMC Neurology · doi:10.1186/s12883-016-0561-z · Cited by 59
McBride, C. L., Akeroyd, J. M., Ramsey, D. J., Nambi, V., Nasir, K., Michos, E. D., Bush, R. L., Jneid, H. M., Morris, P. B., Bittner, V., et al. (2018) · Vascular Medicine · doi:10.1177/1358863x18758914 · Cited by 52
Statin Therapy Improves Outcomes After Valvular Heart Surgery
Fedoruk, L. M., Wang, H., Conaway, M. R., Kron, I. L., & Johnston, K. C. (2008) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2008.01.078 · Cited by 53
Morrison, A. M., Sullivan, A. E., & Aday, A. W. (2023) · Medical Clinics of North America · doi:10.1016/j.mcna.2023.04.004 · Cited by 73
Kizer, J. R., Madias, C. A., Wilner, B. F., Vaughan, C. J., Mushlin, A. I., Trushin, P., Gotto, A. M., & Pasternak, R. C. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.12.051 · Cited by 59
Lipid profiles and outcome in patients treated by intravenous thrombolysis for cerebral ischemia
Nardi, K., Engelter, S. T., Strbian, D., Sarıkaya, H., Arnold, M., Casoni, F., Ford, G. A., Cordonnier, C., Lyrer, P. A., Bordet, R., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182608c82 · Cited by 57
Sobrino, T., Blanco, M., Pérez‐Mato, M., Rodríguez‐Yáñez, M., & Castillo, J. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03770.x · Cited by 53
The Many Roles of Statins in Ischemic Stroke
Zhao, J., Zhang, X., Dong, L., Wen, Y., & Cui, L. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140923210929 · Cited by 60
Rodríguez, F., Lin, S., Maron, D. J., Knowles, J. W., Virani, S. S., & Heidenreich, P. A. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.09.007 · Cited by 54
Yoshimura, S., Uchida, K., Daimon, T., Takashima, R., Kimura, K., Morimoto, T., Tanada, S., Iida, T., Kuroda, J., Nose, A., et al. (2017) · Stroke · doi:10.1161/strokeaha.117.017623 · Cited by 59
Young, L. H., Viscoli, C. M., Schwartz, G. G., Inzucchi, S. E., Curtis, J. P., Gorman, M., Furie, K. L., CONWIT, R. A., Spatz, E. S., Lovejoy, A. M., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034763 · Cited by 55
Cholesterol-Lowering Agents: Statins—For Everyone?
Hadjiphilippou, S., & Ray, K. K. (2019) · Circulation Research · doi:10.1161/circresaha.118.313245 · Cited by 49
Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives
Sander, D., & Kearney, M. T. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5143-1 · Cited by 54
Advances in statin adverse reactions and the potential mechanisms: A systematic review
Zeng, W., Deng, H., Luo, Y., Zhong, S., Huang, M., & Tomlinson, B. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.12.020 · Cited by 71
Statin Rebound or Withdrawal Syndrome: Does It Exist?
Pineda, A. M., & Cubeddu, L. X. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0148-x · Cited by 53
Yeh, P.-S., Yang, C.-M., Lin, S., Wang, W.-M., Chen, P.-S., Chao, T., Lin, H.-J., Lin, K., Chang, C., Cheng, T., et al. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.03.015 · Cited by 56
Atorvastatin: safety and tolerability
Athyros, V. G., Τζιόμαλος, Κ., Karagiannis, A. I., & Mikhailidis, D. P. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2010.495385 · Cited by 54
Kitagawa, K., Hosomi, N., Nagai, Y., Kagimura, T., Ohtsuki, T., Origasa, H., Minematsu, K., Uchiyama, S., Nakamura, M., Matsumoto, M., et al. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.39354 · Cited by 53
Bath, P. M., Geeganage, C. M., Gray, L. J., Collier, T. J., & Pocock, S. (2008) · Stroke · doi:10.1161/strokeaha.107.509893 · Cited by 58
Bangalore, S., Fayyad, R., Kastelein, J. J., Laskey, R., Amarenco, P., DeMicco, D. A., & Waters, D. D. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.10.024 · Cited by 51
Kim, J. S. (2021) · Journal of Stroke · doi:10.5853/jos.2021.01249 · Cited by 56
Nitric oxide signaling in the brain: A new target for inhaled nitric oxide?
Charriaut‐Marlangue, C., Bonnin, P., Pham, H., Loron, G., Léger, P., Gressèns, P., Renolleau, S., & Baud, O. (2013) · Annals of Neurology · doi:10.1002/ana.23842 · Cited by 53
Inpatient statin use predicts improved ischemic stroke discharge disposition
Flint, A. C., Kamel, H., Navi, B. B., Rao, V. A., Faigeles, B. S., Conell, C. A., Klingman, J. G., Hills, N. K., Nguyen‐Huynh, M. N., Cullen, S. P., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182575142 · Cited by 53
Outcome of intracerebral haemorrhage patients pre‐treated with statins
Gomis, M., Ois, Á., Rodríguez-Campello, A., Cuadrado‐Godia, E., Jiménez-Conde, J., Subirana, I., Dávalos, A., & Roquer, J. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02838.x · Cited by 53
Rahimi, K., Majoni, W., Merhi, A., & Emberson, J. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs005 · Cited by 50
Overlap of Diseases Underlying Ischemic Stroke: The ASCOD Phenotyping
Sirimarco, G., Lavallée, P. C., Labreuche, J., Meseguer, E., Cabrejo, L., Guidoux, C., Klein, I. F., Olivot, J., Abboud, H., Adraï, V., et al. (2013) · Stroke · doi:10.1161/strokeaha.113.001363 · Cited by 50
Riaz, H., Khan, A. R., Khan, M. S., Rehman, K. A., Al-Ansari, S., Gheyath, B., Raza, S., Barakat, A. F., Luni, F. K., Ahmed, H. M., et al. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.046 · Cited by 52
Increasing prevalence of vascular risk factors in patients with stroke: A call to action
Otite, F. O., Liaw, N., Khandelwal, P., Malik, A. M., Romano, J. G., Rundek, T., Sacco, R. L., & Chaturvedi, S. (2017) · Neurology · doi:10.1212/wnl.0000000000004617 · Cited by 56
Stroke Prevention in the Very Elderly
Lindley, R. I. (2018) · Stroke · doi:10.1161/strokeaha.117.017952 · Cited by 59
Judge, C. S., Ruttledge, S., Costello, M. M., Murphy, R., Loughlin, E. A., Alvarez‐Iglesias, A., Ferguson, J. P., Gorey, S., Nolan, A. M., Canavan, M. D., et al. (2019) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2019.02.018 · Cited by 51
Atorvastatin Treatment for Men with Lower Urinary Tract Symptoms and Benign Prostatic Enlargement
Mills, I. W., Crossland, A., Patel, A., & Ramonas, H. (2007) · European Urology · doi:10.1016/j.eururo.2007.02.032 · Cited by 50
Statin therapy after first stroke reduces 10-year stroke recurrence and improves survival
Milionis, H. J., Giannopoulos, S., Kosmidou, M. S., Panoulas, V. F., Manios, E. D., Kyritsis, A. P., Elisaf, M., & Vemmos, K. N. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a711cb · Cited by 54
Omer, S. B., Phadke, V. K., Bednarczyk, R. A., Chamberlain, A. T., Brosseau, J. L., & Orenstein, W. A. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv457 · Cited by 55
Sniderman, A. D., Thanassoulis, G., Couture, P., Williams, K., Alam, A., & Furberg, C. D. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.05.004 · Cited by 49
Stroke Prevention: Managing Modifiable Risk Factors
Legge, S. D., Koch, G., Diomedi, M., Stanzione, P., & Sallustio, F. (2012) · Stroke Research and Treatment · doi:10.1155/2012/391538 · Cited by 67
Meretoja, A., Kaste, M., Roine, R. O., Juntunen, M., Linna, M., Hillbom, M., Marttila, R. J., Erilä, T., Rissanen, A., Sivenius, J., et al. (2011) · Annals of Medicine · doi:10.3109/07853890.2011.586361 · Cited by 49
Evolution of intracranial atherosclerotic disease under modern medical therapy
Leung, T. W. H., Wang, L., Soo, Y. O. Y., Ip, V. H. L., Chan, A. Y. Y., Au, L. W. C., Fan, F. S. Y., Lau, A. Y. L., Leung, H., Abrigo, J., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24340 · Cited by 49
Evidence-Based Carotid Interventions for Stroke Prevention: State-of-the-art Review
Morris, D., Ayabe, K., Inoue, T., Sakai, N., Bulbulia, R. A., Halliday, A. W., & Goto, S. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.38745 · Cited by 53
O’Donnell, T. F. X., Deery, S. E., Darling, J. D., Shean, K. E., Mittleman, M. A., Yee, G. N., Dernbach, M. R., & Schermerhorn, M. L. (2017) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2017.03.416 · Cited by 49
Zhang, X., Liu, J., Wang, M., Qi, Y., Sun, J., Liu, J., Wang, Y., Hao, Y., Li, Y., Zhou, M., et al. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.06.011 · Cited by 51
Krasteva, M. P., Lau, K. K., Mordasini, P., Tsang, A. C. O., & Heldner, M. R. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01291-4 · Cited by 56
The beneficial effect of statins treatment by stroke subtype
Martínez‐Sánchez, P., Rivera-Ordoñez, C., Fuentes, B., Ortega-Casarrubios, M. D. L. Á., Idrovo, L. A., & Díez‐Tejedor, E. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2008.02370.x · Cited by 54
Cappellari, M., Deluca, C., Tinazzi, M., Tomelleri, G., Carletti, M., Fiaschi, A., Bovi, P., & Moretto, G. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.05.026 · Cited by 49
Postmenopausal hormone therapy in clinical perspective
Hodis, H. N., & Mack, W. J. (2007) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31802e8508 · Cited by 52
The Role of Pericytes in Ischemic Stroke: Fom Cellular Functions to Therapeutic Targets
Zhou, S., Guo, Z., Zhang, D., Qu, Y., & Jin, H. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.866700 · Cited by 53
Secondary Ischemic Stroke Prevention
Bangad, A., Abbasi, M., & de Havenon, A. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01352-w · Cited by 66
Recent trends in cost‐related medication nonadherence among stroke survivors in the United States
Levine, D. A., Morgenstern, L. B., Langa, K. M., Piette, J. D., Rogers, M. A. M., & Karve, S. J. (2013) · Annals of Neurology · doi:10.1002/ana.23823 · Cited by 56
Statins for the Prevention of Stroke: A Meta-Analysis of Randomized Controlled Trials
Wang, W., & Zhang, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092388 · Cited by 52
Li, J., Lu, Z., Kou, W., Chen, Z., Wu, Y., Yu, X.-H., Zhao, Y., & on behalf of the Chinese Coronary Secondary Prevention Study (CCSPS) Group (2010) · Annals of Medicine · doi:10.3109/07853891003652534 · Cited by 47
Karam, J. G., Loney‐Hutchinson, L., & McFarlane, S. I. (2008) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4572.2008.07967.x · Cited by 48
Goldfarb‐Rumyantzev, A. S., Habib, A. N., Baird, B. C., Barenbaum, L. L., & Cheung, A. K. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.07.023 · Cited by 47
Clinical and anatomic outcomes after carotid endarterectomy
Kang, J. L., Conrad, M. F., Patel, V. I., Mukhopadhyay, S., Garg, A., Cambria, M. R., LaMuraglia, G. M., & Cambria, R. P. (2014) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2013.10.059 · Cited by 49
Zhao, H., Chan, S.-J., Ng, Y., & Wong, P. T. ‐. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067322 · Cited by 54
Markers of instability in high-risk carotid plaques are reduced by statins
Kunte, H., Amberger, N., Busch, M. A., Rückert, R.-I., Meiners, S., & Harms, L. (2008) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2007.11.045 · Cited by 51
Ögren, J., Irewall, A.-L., Söderström, L., & Mooe, T. (2018) · BMC Neurology · doi:10.1186/s12883-018-1158-5 · Cited by 52
Low-Density Lipoprotein Cholesterol
Cannon, C. P. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.033 · Cited by 52
Venous Thrombosis Associated with HMG-CoA Reductase Inhibitors
Lippi, G., Favaloro, E. J., & Sanchis‐Gomar, F. (2013) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0033-1343892 · Cited by 47
Metadata
- Authors
- The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators
- Affiliations
- Université Paris Diderot (FR)
- Corresponding author
- The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-08-10
- Volume
- 355
- Issue
- 6
- Pages
- 549-559
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1546258268
- Cited by
- 2,887
- References
- 21
- Citations by year
- 2026: 86 · 2025: 96 · 2024: 119 · 2023: 112 · 2022: 135 · 2021: 134 · 2020: 139 · 2019: 140 · 2018: 129 · 2017: 132 · 2016: 139 · 2015: 125 · 2014: 142 · 2013: 160 · 2012: 149
- FWCI
- 200.93
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Eisai
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cerebrovascular and Carotid Artery Diseases
- Keywords
- atorvastatin, high-intensity statin therapy, stroke, transient ischemic attack, secondary stroke prevention, LDL cholesterol lowering, hemorrhagic stroke, ischemic stroke, cardiovascular events, elevated liver enzymes, lipid-lowering therapy, mortality, serious adverse events
- MeSH terms
- Atorvastatin, Adult, Cardiovascular Diseases, Cerebral Hemorrhage, Cerebral Infarction, Ischemic Attack, Transient, Drug Therapy, Combination, Female, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Pyrroles, Risk, Proportional Hazards Models, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.